2. Signaling Pathways
  3. Apoptosis
  4. TNF Receptor
  5. TNF Receptor Isoform
  6. TNF Receptor Agonist

TNF Receptor Agonist

TNF Receptor Agonists (18):

Cat. No. Product Name Effect Purity
  • HY-P99046
    Selicrelumab
    		Agonist
    Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study.
  • HY-P99260
    Conatumumab
    		Agonist 98.90%
    Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .
  • HY-P99049
    Sotigalimab
    		Agonist 98.90%
    Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma.
  • HY-161982
    JNU-0921
    		Agonist 99.77%
    JNU-0921 is a potent and orally active CD137 agonist. JNU-0921 increases the mRNA expression of IFN-γ and GZMB. JNU-0921 induces luciferase activity with an EC50 value of 64.07 nM.JNU-0921 enhances effector and memory function of cytotoxic CD8+ T cells (CTLs) and alleviates their exhaustion. JNU-0921 also skews polarization of helper T cells toward T helper 1 type and enhances their activity to boost CTL function. JNU-0921 shows anticancer activity.
  • HY-19916A
    Lisavanbulin dihydrochloride
    		Agonist 99.74%
    Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator, agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti-PD-1 and anti-CTLA-4). Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma.
  • HY-19916
    Lisavanbulin
    		Agonist 99.24%
    Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator, agonistic anti-CD40 antibody, and double immune checkpoint blockade (anti-PD-1 and anti-CTLA-4). Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma.
  • HY-P991179
    MK-4166
    		Agonist 98.20%
    MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 enhances the proliferation of both naïve and tumor-infiltrating T lymphocytes.
  • HY-P991178
    BMS-986156
    		Agonist
    BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody agonist corticosteroid-induced tumor necrosis factor receptor-related protein (GITR). BMS-986156 binds to GITR and promotes activation of T effector cells and inactivates T regulatory cells. BMS-986156 is indicated for use in advanced solid tumor studies.
  • HY-P99470
    Benufutamab
    		Agonist 98.62%
    Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects.
  • HY-P991525
    2141-V11
    		Agonist
    2141-V11 is an anti-CD40 agonist antibody with enhanced binding to FcγRIIB. 2141-V11 results in effective tumor-specific T-cell responses in vivo. 2141-V11 can be used for the study of BCG-unresponsive non-muscle invasive bladder cancer.
  • HY-P990241
    Anti-Mouse GITR (D265A) Antibody (DTA-1)
    		Agonist
    Anti-Mouse GITR (D265A) Antibody (DTA-1) is a mouse-derived IgG1, κ type agonistic antibody, targeting to mouse GITR. The recommed isotype control of Anti-Mouse GITR (D265A) Antibody (DTA-1) is Mouse IgG1 kappa, Isotype Control (HY-P99977).
  • HY-P991510
    CDX-1140
    		Agonist
    CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors.
  • HY-P991455
    PTX-35
    		Agonist
    PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P991529
    AGEN-2373
    		Agonist
    AGEN-2373 is a conditionally active agonist antibody targeting the co-stimulatory receptor CD137. GEN-2373 binds to CD137 without disruption of ligand binding. AGEN-2373 stimulates CD137 under receptor clustering conditions. AGEN-2373 can enhance T cell activity when combined with other checkpoint modulators (e.g. PD-1 antagonist and OX40 agonist). AGEN-2373 can be studied in research for human malignancies.
  • HY-P991460
    Sym029
    		Agonist
    Sym029 is a human IgG monoclonal antibody (mAb) targeting TNFRSF5/CD40. Sym029 can be used in cancer research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P991070
    ADG-106
    		Agonist
    ADG-106 is a fully human agonistic monoclonal IgG4 antibody against CD137 (4-1BB). ADG-106 has the mechanism to activate CD137 via strong FcγRIIB-mediated crosslinking while antagonizing CD137 ligands. The isotype control for ADG-106 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
  • HY-P990240
    Anti-Mouse GITR (LALA-PG) Antibody (DTA-1)
    		Agonist
    Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is a mouse-derived IgG2a, κ type agonistic antibody, targeting to mouse GITR. The recommed isotype control of Anti-Mouse GITR (LALA-PG) Antibody (DTA-1) is Mouse IgG2a kappa, Isotype Control (HY-P99978).
  • HY-101849R
    Fasentin (Standard)
    		Agonist
    Fasentin (Standard) is the analytical standard of Fasentin. This product is intended for research and analytical applications. Fasentin, a potent glucose uptake inhibitor, inhibits GLUT-1/GLUT-4 transporters. Fasentin preferentially inhibits GLUT4 (IC50=68 μM) over GLUT1. Fasentin is a death receptor stimuli (FAS) sensitizer and sensitizes cells to FAS-induced cell death. Fasentin is also a tumor necrosis factor (TNF) apoptosis-inducing ligand sensitizer. Fasentin blocks glucose uptake in cancer cell lines and has anti-angiogenic activity.